


## CORE ASSAY LIST 2008

### SAFETY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSP - 01	<i>In vitro</i> pharmacology, isolated tissue assay: human atrial appendage	<p><b>Test model:</b> Measurement of a compound's effect on cardiac muscle contractility for early identification of compounds that adversely affect either rate of beating (chronotropism) or force of contraction (inotropism).</p> <p><b>Assay format:</b> Concentration-effect curve to test compound compared to a reference compound.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	1 client compound & 1 reference compound each in 1 donor
PZSP - 02	<i>In vitro</i> pharmacology, isolated tissue assay: human coronary artery: large	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause coronary vasoconstriction.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSP - 03	<i>In vitro</i> pharmacology, isolated isolated tissue assay: human coronary artery: small, 'resistance-like'	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause coronary vasoconstriction.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSP - 04	<i>In vitro</i> pharmacology, isolated isolated tissue assay: human middle cerebral artery: large	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause cerebral vasoconstriction/vasodilatation.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor

# SAFETY PHARMACOLOGY

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZSP - 05	<i>In vitro</i> pharmacology, isolated tissue assay: human middle cerebral artery: small, 'resistance-like'	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause cerebral vasoconstriction/vasodilatation.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	6 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor
PZSP - 06	<i>In vitro</i> pharmacology, isolated tissue assay: human bronchus: large airways	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause bronchoconstriction.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSP - 07	<i>In vitro</i> pharmacology, isolated tissue assay: human bronchus: small airways	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause bronchoconstriction.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSP - 08	<i>In vitro</i> pharmacology, isolated tissue assay: human pulmonary artery: large	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause pulmonary vasoconstriction/vasodilatation.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound and a vehicle control.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds tested in duplicate, 1 reference compound & 1 vehicle control in 1 donor
PZSP - 09	<i>In vitro</i> pharmacology, isolated tissue assay: human pulmonary artery: small, 'resistance-like'	<p><b>Test model:</b> Measurement of a compound's effect on muscle contractility for early identification of compounds that may cause pulmonary vasoconstriction/vasodilatation.</p> <p><b>Assay format:</b> Concentration-effect curve to test compounds compared to a reference compound.</p> <p><b>Data format:</b> MS Word™ report containing analyzed data. Raw data files (Notocord-hem) available if required.</p>	3 weeks After receipt of clients' compounds	2 x 1mg	2 client compounds & 1 reference compound in 1 donor